logo
#

Latest news with #JeremyMorgan

The 91-year record Salt Lake City won't break this winter
The 91-year record Salt Lake City won't break this winter

Yahoo

time19-03-2025

  • Climate
  • Yahoo

The 91-year record Salt Lake City won't break this winter

Jeremy Morgan was one of many residents who spent Tuesday morning clearing out their own or a neighbor's driveways after the Wasatch Front received several inches of snowfall overnight. Mid-March valley snowfall is very normal in Utah, but the latest storm pattern has been a bit of a rarity this season. The last few storms have finally helped Salt Lake City avoid a record set over nine decades ago. With 3.4 inches of snow at Salt Lake City International Airport between Monday night and Tuesday morning, the latest storm is Salt Lake City's largest snowstorm of this season, surpassing all storms that passed through during meteorological winter (the three calendar months with the lowest average temperatures). Some additional snowfall was possible through Wednesday morning, which could extend the total. Some other parts of the city received as much as 9 inches of snow. As of noon Tuesday, Utah's capital city extended its seasonal snowfall to 18.1 inches with the latest storm. The running total also surpassed 14.3 inches on Sunday, which — set during the 1933-1934 season — remains the lowest seasonal snowfall total Utah's capital has recorded since the National Weather Service began collecting city weather data in 1874. So how did Salt Lake City almost break a record set 91 years ago, and why did trends suddenly change? It all has to do with storm dynamics over the past few months. Utah's meteorological winter — a period from Dec. 1, 2024, through Feb. 28 of this year — mostly produced two storm types: drier cold fronts that came in from Canada or wetter storms that tapped into the air from the southwest, which kept them warm enough to not produce much valley snow, Alex DeSmet, a meteorologist at the National Weather Service, explained back in January. Some storms broke these trends, but Salt Lake City received 2.99 inches of precipitation throughout meteorological winter but just 10.4 inches of snowfall. It normally receives 4.13 inches of precipitation during the season, including 35.5 inches of snow, based on records from 1991 to 2020. That differs from the 1933-1934 season, which was part of the city's driest water year on record. Salt Lake City received just 8.16 inches of precipitation from Oct. 1, 1933, through Sept. 30, 1934, during what was one of Utah's hottest and driest periods in modern history. The two storm dynamics also led to major shifts in snowpack totals across regions, helping northern Utah have a fairly normal season, while southern Utah ended winter on the brink of a record-low snowpack collection. However, to the delight of some and the dejection of others, recent storms have essentially merged the two trends into a more familiar wintery pattern, says KSL meteorologist Matt Johnson. He explains that low-pressure systems have formed over the Bering Sea and dropped into the Gulf of Alaska, gathering moisture before entering the Pacific Northwest and then Utah. They've brought in northwest wind flow, which is a key factor in Utah's valley snow. "The last couple of storms have definitely been colder," he said. "Earlier in the year, we were seeing a lot of subtropical influence — we were seeing the storms bringing a ton of water, but they weren't bringing the cold air. ... This time, we're getting the storm with the full package." Salt Lake City's seasonal snow total, as of noon Tuesday, is the fourth-lowest all-time, but it could continue to move away from record lows over the next few weeks if the stormy trend can continue. April 16 is the city's average last day of snowfall. The latest storm also produced impressive valley numbers in other cities: Providence, Cache County: 10 inches. Fillmore: 9 inches. Tooele: 9 inches. Bountiful Bench: 8 inches. Centerville: 5 inches. Holladay: 4 inches. South Jordan: 4 inches. More importantly, snow has fallen in the mountains across all of the state's regions again, raising the statewide snowpack average to 101% of its median average for this point in the year, as of noon Tuesday. Many basins across northern Utah are above 100% of its mid-March average, while central Utah sites are back to 73% to 102% and southern Utah sites are 48% to 81% of average — leaping out of record-low status. Johnson said some additional snowfall is possible Wednesday morning, while mountains are on tap to receive additional snow on Thursday and Saturday. Full seven-day forecasts for areas across Utah can be found online, at the KSL Weather Center.

2 old buildings help Northwest Florida firefighters, officials say
2 old buildings help Northwest Florida firefighters, officials say

Yahoo

time06-02-2025

  • General
  • Yahoo

2 old buildings help Northwest Florida firefighters, officials say

FORT WALTON BEACH, Fla. (WKRG) — Old buildings may not be the prettiest sights, but Fort Walton Beach officials say they can help first responders prepare for emergencies. According to a City of Fort Walton Beach Facebook post, Fort Walton Beach Fire Department and Ocean City-Wright Fire Control District firefighters practiced their skills on two local buildings that were getting ready for demolition. UPDATE: Pensacola bridge reopens after deadly crash early Wednesday morning Training opportunities were available at the old Okaloosa County School Board building and the old Northwest Florida Daily News office. Firefighting officials said that the availability to practice in the two buildings before demolition allowed crews to practice their skills in a real-world environment. 'It's great to have real buildings to train on,' Fort Walton Beach Fire Chief Jeremy Morgan said. 'It's an opportunity to practice some firefighting techniques, like forcible entry through doors, without having to worry about destroying property.' Man drives motorized shopping cart on Airport Boulevard, gets arrested: Mobile PD Officials thanked Larry Ashley and Murphy USA for allowing the crews to use the buildings. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe
Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

Associated Press

time30-01-2025

  • Health
  • Associated Press

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

GALASHIELS & MARLOW, England & BAAR, Switzerland--(BUSINESS WIRE)--Jan 30, 2025-- Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and Swixx BioPharma AG today announced that the Croatian National Health Insurance Fund (NHIF) and the Bulgarian Ministry of Health have both approved the reimbursement of POTELIGEO ® (mogamulizumab) for adult patients with mycosis fungoides (MF), and Sézary syndrome (SS). MF and SS are two subtypes of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma that presents and persists in the skin and can cause debilitating physical, emotional and social challenges. 1 MF—the most common CTCL subtype—accounts for approximately 60% of all CTCLs. 2 With an average time to diagnosis of 3-4 years, MF is typically characterised by skin symptoms including patches or plaques, skin redness and tumours. 3,4 SS is much rarer, accounting for around 5% of CTCLs, 5 and is more aggressive, causing severe itching, erythroderma, intense scaling of the skin and frequent hair loss. 6 Jeremy Morgan, President of Kyowa Kirin International, commented: 'I am delighted that the Croatian and Bulgarian authorities have agreed to reimburse POTELIGEO for MF and SS patients. Both decisions are important milestones for people impacted by these rare and challenging forms of CTCL, and with mogamulizumab now reimbursed in more than 20 countries across the EMEA region we remain as committed as ever to delivering life changing value for people impacted by under-diagnosed and under-served diseases, and making more people smile.' Poteligeo is distributed in Central and Eastern Europe by Swixx, on behalf of KKI. The two companies signed a Promotion and Distribution Agreement in October 2022. Under the terms of the agreement, Swixx will exclusively market, promote and distribute mogamulizumab in both Croatia and Bulgaria, among other countries. 'At Swixx, our mission is to unlock access to innovative medicines, and the recent reimbursement approvals in Croatia and Bulgaria mark significant progress in improving therapeutic options for patients with MF and SS in those markets,' said Dezso Martha, Chief Operating Officer of Swixx. 'We will continue working closely with health authorities, the scientific community, and Kyowa Kirin to expand access to this important medicine, ensuring better outcomes for patients across our Central and Eastern European countries.' With Croatian reimbursement effective as of 15 th November 2024, and Bulgaria's Ministry of Health confirming reimbursement as of 2 nd January 2025, both decisions build on the inclusion of POTELIGEO ® (mogamulizumab) in the Polish Ministry of Health's Drug Programme announced in July 2024 and the ongoing expansion of access to patients across Central and Eastern Europe (CEE). About Poteligeo (mogamulizumab) Mogamulizumab is a first-in-class humanised monoclonal antibody directed against CC-chemokine receptor 4 (CCR4), a protein consistently expressed on cancerous cells seen in both MF and SS. 7-9 Once mogamulizumab binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells. 10 About MF and SS MF and SS are two subtypes of CTCL, which is itself a rare form of non-Hodgkin's lymphoma that presents and persists in the skin. 1 CTCL is treatable, but is not generally considered to be curable, and there has been a clear unmet need for novel treatment options. As well as the obvious impact of symptoms upon patients, there can be significant erosions to quality of life for those caring for an individual living with CTCL. 11 MF and SS are characterised by localisation of cancerous white blood cells called T lymphocytes (T cells), to the skin. 12 These cancerous T cells consistently express a protein called CCR4, which enables them to move from the blood to the skin. 7-9 When these cancerous T cells move to the skin, this results in the visible early skin symptoms of red patches or plaques which can resemble psoriasis or eczema in the early stages of the disease. 6 Later, for some patients, skin involvement may evolve to include tumours or reddening of the majority of the skin's surface (erythroderma). MF—the most common CTCL subtype—accounts for approximately 60% of all CTCLs 2 and is typically indolent, characterised by skin symptoms including patches or plaques, skin redness and tumours. 3,4 SS is much rarer, accounting for around 5% of CTCLs, 5 and is more aggressive, 6 with high levels of blood involvement. 5 It can cause severe itching, erythroderma, intense scaling of the skin and frequent hair loss. 6 CTCL can take, on average, between 2 and 7 years for individuals to receive a confirmed diagnosis. 6 About Kyowa Kirin Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by severe and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions – Japan, Asia Pacific, North America, and EMEA/International. You can learn more about the business of Kyowa Kirin at: About Swixx BioPharma AG Swixx BioPharma is one of the fastest-growing, largest, intercontinental commercial platforms for the biopharmaceutical industry. Swixx operates subsidiaries across Central and Eastern Europe, Greece, Russia, several Eurasian countries, the Middle East, and via Biopas, a Swixx BioPharma company, in almost 20 Latin American countries. Swixx BioPharma Group has over 1,600 employees and sales likely to exceed a billion Euros in 2024. The company has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. CONTACT: Contacts for Kyowa Kirin Co., Ltd.: Media KEYWORD: UNITED KINGDOM SWITZERLAND EUROPE CROATIA BULGARIA SOURCE: Kyowa Kirin International Copyright Business Wire 2025. PUB: 01/30/2025 05:05 AM/DISC: 01/30/2025 05:06 AM

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store